The exclusion of patients with worsening psoriasis from meta-analyses of trials that examine biologic therapies for type-plaque psoriasis reveal that serious adverse events (SAEs) are higher with biologic therapies than placebo, which suggest that findings from many meta-analyses do not reflect the real-world safety of biologic agents for psoriasis. This is according to a study research published in the British Journal of Dermatology.

In this study, researchers from France analyzed 51 randomized clinical trials in the Living Network Cochrane Review that compared a biologic therapy to placebo in patients with moderate to severe plaque psoriasis who required systemic treatment (N=24,820).

Trials included in this analysis included 1 anti-tumor necrosis factor (TNF) alpha arm, 1 anti-interleukin (IL)-17 arm, 1 anti-IL-23 arm, and 1 anti-IL-12/23 arm. The primary outcome of the analysis included the number of SAEs with biologic agents vs placebo after cases of psoriasis worsening were excluded. An additional secondary outcome included the number of adverse events (AEs) of special interest.

The mean age of the overall population was 45 years, and the mean baseline PASI score was 20.5. A higher percentage of patients included in all 51 trial were men compared with women (69% vs 31%, respectively). Approximately 25% (n=6287) of the population were randomly assigned to a placebo group.

In the analysis that included cases of psoriasis worsening, there was no statistically significant difference between biologic therapies and placebo in terms of the risk for occurrence SAEs (risk ratio [RR], 1.09; 95% CI, 0.88-1.36; P =.43). When the investigators excluded cases of psoriasis worsening, however, biologicl therapy was associated with a significantly higher risk for SAEs (RR, 1.30; 95% CI, 1.02-1.65; P =.03).

Separated by drug classes, the analysis revealed RRs of 1.68 (95% CI, 1.11-2.54; P =.01) for anti-TNF-alpha, 1.28 (95% CI, 0.88-1.85; P =.20) for anti-IL-17, 0.95 (95% CI 0.59-1.52; P =.83) for anti-IL-23, and 1.18 (95% CI 0.72-1.94; P =.51) for anti-IL-12/23. The small number of AEs of special interest in these analyses prevented the researchers from examining this outcome.

According to the investigators, the reporting of psoriasis worsening has changed over time, which made indirect comparisons not possible by network meta-analysis.

Based on these findings, the investigators added that the results for SAEs overall and SAEs excluding disease worsening should be presented in the results of RCTs and so in systematic reviews and meta-analyses.

Reference

Afach S, Chaimani A, Evrenoglou T, et al. Meta-analysis results do not reflect the real safety of biologics in psoriasis [published online May 23, 2020]. Br J Dermatol. doi: 10.1111/bjd.19244

Read this article:

More SAEs With Biologic Agents vs Placebo in Treatment of Psoriasis - Dermatology Advisor

The global Chronic Plaque Psoriasis Therapeutics market gives detailed Evaluation about all of the Important aspects related to the market. The study on international Chronic Plaque Psoriasis Therapeutics economy, offers deep insights regarding the Chronic Plaque Psoriasis Therapeutics market covering all of the crucial aspects of the marketplace. Moreover, the report provides historical information with prospective forecast over the forecast period. Various important factors like market trends, revenue growth patterns market stocks and supply and demand are contained in almost all the market research document for every business. A number of the important aspects analysed in the report contains market share, creation, key regions, revenue rate as well as key players.

The study of various sections of the international market are also Covered in the research report. In addition to that, for the forecast periods conclusion of factors such as market size and the competitive landscape of the market is analysed in the report. Due to the rising globalization and digitization, there are new trends coming to the marketplace daily. The research report provides the detailed analysis of all of these tendencies.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/21442

In addition, the Chronic Plaque Psoriasis Therapeutics marketplace report also supplies the Latest trends in the global Chronic Plaque Psoriasis Therapeutics market with the assistance of primary in addition to secondary research methodologies. Also, the analysis report on Chronic Plaque Psoriasis Therapeutics market gives a wide analysis of the market including market overview, production, manufacturers, dimensions, price, value, growth rate, income, prices, export, consumption, and sales revenue of this global Chronic Plaque Psoriasis Therapeutics market. On the other hand, the Chronic Plaque Psoriasis Therapeutics market report also studies the market status for the prediction period. However, this will help to grow the advertising opportunities throughout the world as well as major market suppliers.

The key manufacturers engaged in developing the chronic plaque psoriasis therapeutics market include Abbvie, Inc., Novartis International AG, Pfizer, Inc., Merck & Co., Astelllas Pharma, Inc., GlaxoSmithKline Plc and others.

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/21442

The Chronic Plaque Psoriasis Therapeutics market report provides helpful insights for Every established and innovative players throughout the globe. Additionally the Chronic Plaque Psoriasis Therapeutics market report provides accurate evaluation for the shifting competitive dynamics. This study report includes a complete analysis of future growth in terms of the evaluation of the mentioned forecast period. The Chronic Plaque Psoriasis Therapeutics market report offers a comprehensive analysis of the technological advancement prognosis over time to be aware of the market growth prices. The Chronic Plaque Psoriasis Therapeutics market report also has progressive analysis of the huge number of unique facets which are boosting or operating in addition to regulating the Chronic Plaque Psoriasis Therapeutics market growth.

A systematized methodology can be utilized to create a Report on the Global Chronic Plaque Psoriasis Therapeutics market. For the research of economy on the Conditions of study Approaches, these techniques are useful. All of the Information Regarding this Products, makers, vendors, clients and much more is covered in research reports. Various important factors like market trends, revenue Growth patterns market stocks and demand and supply are included in virtually all The market study report for every industry. Adaptation of fresh ideas and Accepting the most recent trends are a few the reasons for virtually any markets growth. The Global Chronic Plaque Psoriasis Therapeutics market research report provides the profound understanding about the Regions in which the marketplace is impactful.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/21442

Read more from the original source:

Market Players Eye Opportunities in Emerging Economies to Gain Ground in the Chronic Plaque Psoriasis Therapeutics Market 2017 2025 - Jewish Life...

Division/SchoolBristol Medical SchoolContract typeOpen EndedWorking patternFull or Part timeSalary33,797 to 38,017 Grade I / 38,017 to 42,792 Grade J per annumClosing date for applications09-Aug-2020

We are seeking to appoint a Research Associate/Senior Research Associate in molecular epidemiology/bioinformatics to analyse genomic data generated by Biomarkers in Atopic Dermatitis and Psoriasis (BIOMAP,https://www.biomap-imi.eu/).

The post-holder will be a key member of the BIOMAP work package 3 data analysis team (https://www.biomap-imi.eu/about/work-packages) to determine causal relationships between intermediate omics traits and Atopic Dermatitis and Psoriasis subtypes to identify potential target mechanisms. The postholder will perform comprehensive analysis of DNA methylation and gene expression data using blood and skin samples from multiple cohorts in order to link molecular signatures to Atopic Dermatitis and Psoriasis subtypes. They will examine the identified associations over the life course using longitudinal data and will use Mendelian Randomization, to determine which EWAS/TWAS associations have causal evidence. They will also use Bayesian colocalization analysis to identify the likely causal genes implicated by GWAS of Atopic Dermatitis and Psoriasis subtypes and compare molecular signatures in isolated cell types to determine the tissue/cell type-specific regulatory component of differentially expressed/methylated signatures. Feature selection methods will also be used to predict Atopic Dermatitis and Psoriasis subtypes.

The postholder will be part of the MRC Integrative Epidemiology Unit (IEU) at the University of Bristol and will be aligned with multiple programmes (epigenetic epidemiology and Mendelian randomization) within the unit. The work undertaken in this position will be driven by the objectives of BIOMAP, however will allow (and encourage) the development of a personal research portfolio.

The appointment will be at Grade I or J, dependant on the extent of relevant research experience, is offered as an open ended contract with 3 years initial funding. This could be on a full-time or part-time basis, or could allow time to be split with another project. The post is ideally suited to someone with a PhD in molecular epidemiology, bioinformatics or a closely related discipline. You will have experience using statistical programming languages (such as R) and preferably experience of working with large-scale molecular datasets. You will have experience of applied statistical analysis and understanding of EWAS, TWAS and preferably also Mendelian randomization methods.

The successful applicant will be based within the MRC Integrative Epidemiology Unit at the University of Bristol (IEU) located within the Bristol Medical School.

We strongly encourage interested applicants to make informal enquiries to Dr Josine Min (josine.min@bristol.ac.uk) or Dr Lavinia Paternoster (l.paternoster@bristol.ac.uk).

We welcome applications from all members of our community and are particularly encouraging those from diverse groups, such as members of the LGBT+ andBAME communities, to join us.

Read more:

Research Associate/Senior Research Associate in Molecular Epidemiology job with UNIVERSITY OF BRISTOL | 213189 - Times Higher Education (THE)

Dermatology biologics refers to agents synthesized from the products of living organisms which are used for dermatologic treatment. Every year, several million people are affected by skin-related diseases across the world. Dermatology biologics are becoming significantly beneficial over conventional system therapies due to their target-specific mechanism. Dermatology biologics target specific sites in the immune-pathogenesis pathway of the disease. Dermatology biologics are widely used for the treatment of severe psoriasis, psoriatic arthritis, other types of arthritis and inflammatory bowel diseases. These biologics have revolutionized the treatment of various dermatologic diseases. The first biologic for the treatment of these diseases was approved in 2003, today there are 10 FDA approved biologics in the market to treat moderate to severe plaque psoriasis, which is expected to increase the demand of dermatology biologics over the forecast period.

To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/23005

Dermatology Biologics Market: Drivers and Restraint

Dermatology Biologics market will witness promising growth due to rising prevalence of chronic diseases. Introduction of various innovative products in the form of dermatology biologics and drug-releasing implants, as a result of research and development and continuous efforts to invent treatment alternatives, are also contributing to market growth. Efficiency and target specific approach of dermatology biologics and high adoption rate of dermatology biologics in psoriasis treatment are the other driving factors for the market growth. However, the availability of a limited number of dermatology biologics, stringent regulatory norms associated with the approval of dermatology biologics, severe side effects of dermatology biologics and expensive nature of dermatology biologics may hamper the dermatology biologics market growth during the forecast period.

To receive Methodology request here@ https://www.persistencemarketresearch.com/methodology/23005

Dermatology Biologics Market: Segmentation

The global market for Dermatology Biologics can be segmented on the basis of product type, indication, distribution channel and geography:

Dermatology Biologics Market: Overview

The global dermatology biologics market is witnessing rapid growth due to the emergence of innovative dermatology biologics in recent years. The FDA recently approved Janssens guselkumab (Tremfya) for the treatment of plaque psoriasis. The overall market is expected to report promising growth as the epidemiologic studies have revealed that prevalence of psoriasis in the UK is estimated to be at 1.3%2.2%. Promising revenue growth is expected in the dermatology biologics market during the forecast period due to the introduction of novel dermatology biologics products in near future.

To receive extensive list of important regions, Request TOC here @ https://www.persistencemarketresearch.com/toc/23005

Dermatology Biologics Market: Region-wise Outlook

On the basis of geography, the global Dermatology Biologics market is segmented into six key regions North America, Latin America, Europe, Asia Pacific excluding China and Middle East & Africa. North America followed by Europe will continue to dominate the global dermatology biologics market in terms of revenue owing to rising technological advancements in healthcare and systematic drug review processes. The Europe dermatology biologics market is driven by growing funding for the development of dermatology biologics available through public-private partnerships, availability of high-quality research infrastructure and innovative strategies being developed by drug makers. Furthermore, rising disease incidences in emerging countries are expected to prove to be favorable for the growth of the dermatology biologics market

Dermatology Biologics Market: Key Market Participants

The key market players in the global Dermatology Biologics market include Pfizer Inc., AstraZeneca, Genzyme, Merck KGaA., Johnson & Johnson, Amgen, Valeant Pharmaceuticals International, Inc. and other and others. The key players have indulged in strategic initiatives, such as collaborations, acquisitions and mergers and product launches in the recent years.

Excerpt from:

Global Dermatology Biologics Market Revenue to Witness Rapid Growth in the Near Future - Jewish Life News

NEW DELHI, July 11: Indias drug regulator has approved Itolizumab, used to cure skin ailment psoriasis, for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress, officials said.Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India Dr V G Somani approved monoclonal antibody injection Itolizumab for restricted emergency use for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said on Friday.The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome, an official told PTI.It is already an approved drug of Biocon for treating psoriasis for last many years, the official said.Written informed consent of each patient is required before the use of this drug, he said. (PTI)

The Leading Daily of Jammu and Kashmir , India

Original post:

Drug regulator okays psoriasis injection for limited use in treating COVID-19 patients - Daily Excelsior

Aditi Tandon

Tribune News Service

New Delhi, July 11

Itolizumab, a monoclonal antibody drug being used in India to treat severe chronic plaque psoriasis a skin condition has now been granted the Restricted Emergency Use authorisation by the Drugs Controller General of India (DCGI) for administration to moderate and severe COVID-19 patients.

Pharma firm Biocon has been manufacturing and marketing this drug for the treatment of patients with moderate to severe chronic plaque psoriasis since 2013 under brand name Alzumab.

This indigenous drug has now been repurposed for COVID-19.

Biocon presented the Phase II clinical trial results generated in the COVID-19 patients to the DCGI. The results of these trials were deliberated in the Subject Expert Committee of the DCGIs office.

The details of the primary endpoint of mortality and other key endpoints of lung function such as improvement in oxygen saturation were presented. Key inflammatory markers were presented to have reduced significantly with the drug thereby preventing hyper-inflammation in COVID-19 patients.

After detailed deliberation and recommendations of the committee, the DCGI has decided to grant permission to market the drug under Restricted Emergency Use of the drug for the treatment of Cytokine Release Syndrome (CRS) in moderate to severe Acute Respiratory Distress Syndrome (ARDS) patients due to COVID-19, subject to some conditions such as informed consent of patients and a risk management plan to be used in the hospital setup only.

The drug will not be available off the shelf.

The average cost of treatment with this indigenous drug is also lesser than comparable drugs which are part of the investigational therapies indicated in the Clinical Management Protocol for COVID-19 of the Ministry of Health and Family Welfare.

More here:

Drug regulator okays psoriasis injection for restricted emergency use in treating COVID-19 patients - The Tribune India

Indias drug regulator has approved Itolizumab, used to cure skin ailment psoriasis, for restricted emergency use on COVID-19 patients with moderate to severe acute respiratory distress, officials said.

Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India Dr V G Somani approved monoclonal antibody injection Itolizumab for restricted emergency use for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said on Friday.

The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome, an official told PTI.

It is already an approved drug of Biocon for treating psoriasis for last many years, the official said. Written informed consent of each patient is required before the use of this drug, he said.

Here is the original post:

Covid-10 Treatment: Psoriasis injection Itolizumab gets nod for limited use in treating coronavirus patients - Financial Express

Psoriasis is an autoimmune disease which is characterized by scaly patches of skin with inflammation and causes excessive production of new skin cells. Presently, there are no long term therapeutics available for the treatment of psoriasis. Chronic Plaque psoriasis is the one of the most common type of psoriasis. This disease condition is associated with several risk factors such as infection, psychological stress and others. Diagnosis of chronic plaque psoriasis is based on clinical appearance, is the case is severe then biopsy is recommended by the healthcare professionals in order to distinguish it from other conditions such as seborrheic dermatitis, ichen simplex chronicus and others.

To remain ahead of your competitors, request for a sample [emailprotected]

https://www.persistencemarketresearch.com/samples/21442

Increasing uptake of biological drugs is one of the major factor propelling the growth of the global chronic plaque psoriasis therapeutics market. Advances in inflammation and immunology research, introduction of innovative drugs and increased focus on the usage of combination therapies are further accentuating the demand for chronic plaque psoriasis drugs. Adverse side effects, however, side-effects associated with the treatment such as risk of skin cancer, headache, hair loss, suppression of immunity and others could pose a major threat to the global chronic plaque psoriasis therapeutics market. Ixekizumab, tofacitinib, baricitinib, tregalizumab, ponesimod, AbGn-168H, E-6201, briakinumab, adalimumab and others are some of the drugs currently in clinical trials for the treatment of chronic plaque psoriasis.

To receive extensive list of important regions, Request Methodology here @

https://www.persistencemarketresearch.com/methodology/21442

Geographically, North America forms the largest regional market for chronic plaque psoriasis therapeutics. In addition, developed countries such as Germany, France, Spain, Italy, the U.K and Japan accounts for the second largest share of the global chronic plaque psoriasis therapeutics market due to emergence of new formulations.

The key manufacturers engaged in developing the chronic plaque psoriasis therapeutics market include Abbvie, Inc., Novartis International AG, Pfizer, Inc., Merck & Co., Astelllas Pharma, Inc., GlaxoSmithKline Plc and others.

You Can Request for TOC Here @ https://www.persistencemarketresearch.com/toc/21442

Go here to read the rest:

Revenue from the Sales of Chronic Plaque Psoriasis Therapeutics Market to Increase Exponentially During 2018 2026 - Cole of Duty

The growth of thepsoriasis drugs marketis attributed to the growing use of topical corticosteroids products and psoriasis treatment across the globe. According to a latest research by the company, the global corticosteroid psoriasis drugs treatment market is expected to account for over US$ 6,509 Mn in terms of value by 2028 end.

The report projects that the psoriasis drugs treatment market will witness significant growth with average year-on-year growth rate pegged at 7.1% through 2028. The report lists out the key points being considered by the manufacturers of psoriasis drugs to emerge and gain profit in the long run in psoriasis drugs market.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/25102

Company Profile

The North America psoriasis drugs market is expected to expand at significant CAGR and to be the dominant revenue-generating psoriasis drugs market due to large presence of dermatology clinics and facilities. Europe is also expected to be one of the leading regional markets for psoriasis drugs as most of the major academic research institutes are located in the region.

Psoriasis Drugs Market: Analysis

Combination therapeutics and product innovations and are factors expected to drive the need for easy and non-invasive treatment for patients undergoing psoriasis treatment and thus, will lead to greater product penetration in the psoriasis drugs treatment market. In this regard, the National Psoriasis Foundation reported that in 2016, around 1,200 patients in the U.S. opted for new combinational therapies.

The use of psoriasis drugs in combination with other therapies for treating psoriasis is far more effective in the long run. To minimize side effects associated with psoriasis drugs, such as hypertension, swelling, rashes, and inflammatory bowel disease caused by traditional drugs, physicians often suggest the use of combination therapies along with psoriasis drugs.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/25102

Using the treatment has a positive impact on the patient. This factor is expected to fuel the demand for psoriasis drugs used in combination and consequently boost the growth of the psoriasis drugs market.

Plaque psoriasis is the first most prominent type of segment in the global psoriasis drugs market. Approximately 90% of psoriasis types are chronic plaque psoriasis, which are characterized by red patches covered with a whitish buildup of dead cells, and are well-demarcated, thick, often symmetrically distributed scaly red plaques.

Although the plaques can affect any part of the skin, they are majorly found on the surface of the elbows, knees and scalp. According to the WHO, 92% patients with psoriasis suffer from severe scaling of skin, especially found in plaque psoriasis.

The global psoriasis drugs market is segmented based on product type, drug class, disease indication, and distribution channel. Based on product type, the psoriasis drugs market has been segmented into topical, oral, and injectable.

The topical product type segment in psoriasis drugs market is expected to be the dominant segment holding maximum share in the global psoriasis drugs market as they are mostly preferred by the patients. Topical psoriasis drugs are applied to the skin in an easy way and are generally the first line of defense in treating psoriasis.

Topicals normalize excessive cell reproduction and reduce psoriasis inflammation. Topicals are lotions, creams, gels, ointments and shampoos. Patients with mild psoriasis are able to tackle their skin complaint with topical treatment. Moderate to severe psoriasis mainly needs additional therapy or oral psoriasis drugs.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/25102

Based on distribution channel, the psoriasis drugs market has been segmented into retail pharmacies, hospital pharmacies and e-commerce.

In terms of revenue, the retail pharmacies segment dominated the global psoriasis drugs market in 2017 and is projected to continue to do so throughout the forecast period. The retail pharmacies segment in psoriasis drugs market is expected to hold a large share in the psoriasis drugs treatment market.

In terms of revenue, the drug class segment in the global psoriasis drugs market is expected to hold significant share over the forecast period. Besides, the segment is expected to exhibit large investment opportunities for companies operating in psoriasis drugs market throughout the forecast period.

Read more from the original source:

Psoriasis Drugs Market 2028 Key Insights and COVID-19 Business Impact - 3rd Watch News

The opportunity analysis covered to understand the North America and Europe phototherapy treatment market for acne and psoriasis, makes this new publication an exclusive one. After a thorough study of the market, our expert team of analysts in the healthcare domain went the extra mile to offer in-depth insights into the market. While studying the market the first important feature we have observed is that this market is likely to witness moderate growth during the 10 year projected period. After a detailed study of the future scenario of the overall market, it was easy for our analysts to identify the macroeconomic factors such as the economic burden of skin diseases and societal habits influencing the phototherapy treatment market for acne and psoriasis in North America and Europe. The report titled Phototherapy Treatment Market for Acne and Psoriasis: North America and Europe Industry Analysis 2012 2016 and Opportunity Assessment 2017 2027 provides detailed information on how the lack of robust clinical evidence on various disease conditions is limiting the growth of the phototherapy treatment market for acne and psoriasis in the regions of North America and Europe.

Request Report [emailprotected]https://www.futuremarketinsights.com/reports/sample/rep-gb-na-4297

One astonishing fact we have come across while inspecting this market is that even in the most developed regions such as North America and Europe, not much research has been done on the other light therapies used in the treatment of acne and psoriasis conditions except blue light and UVB therapy. On the other hand while covering the disease epidemiology we have observed that prevalent cases of acne and psoriasis were remarkable in both the regions especially Europe in 2015.

Is the home-based phototherapy system a solution to limit the rising incidents of the disease?

Usually, phototherapy is an office based treatment procedure. However, lack of sufficient phototherapy units and the majority of phototherapy centres being located in urban areas are forcing patients to choose alternative treatments for their dermatological conditions. An increasing adoption of home-based phototherapy systems is creating huge opportunities for manufacturers. Home based phototherapy reduces patient hassles like transportation issues and the long waiting time in clinics, among others. In addition to this, it also reduces the direct and indirect medical costs of patients.

Our unique analysis of the classification of markets in various segments

According to our analysis, North America represents the most lucrative market, followed by Western Europe and Eastern Europe.

Hospitals end user segment dominates the global market; however, home care settings are becoming the choice of service for patientsBlue light therapy is gaining more traction in phototherapy owing to its benefits in treating acnePlaque psoriasis sub-segment dominates the market in the psoriasis disease segment due to rise in psoriasis patient populationInternational monoclonal antibody conference reports our key source while researching this market

While inspecting the North America and Europe phototherapy treatment market for acne and psoriasis in detail, we have referred to the annual reports, publications, and presentations of product providers. Our analysts have also considered key winning strategies followed by phototherapy treatment market for acne and psoriasis product manufacturers. We have carried out systematic and exhaustive secondary research to analyse the required data points to arrive at the overall market numbers. Detailed questionnaires have been developed for each node in the value chain to extract the required market information through primary research interviews. Data acquired through research is represented using charts, infographics, presentation of key findings by region and providing strategic recommendations and actionable insights for critical decision making.

North America and Europe Phototherapy Treatment for Acne and Psoriasis Market Taxonomy

By Disease Type

Psoriasis

Guttate Psoriasis

Inverse Psoriasis

Pustular Psoriasis

Erythrodermic Psoriasis

Plaque Psoriasis

Acne

Acne Vulgaris

Acne Conglobata

Acne Fulminans

Gram-Negative Folliculitis

Acne Rosacea

Pyoderma Faciale

By Phototherapy Type

Blue Light Phototherapy

Red Light Phototherapy

Intense Pulsed Light (IPL) Phototherapy

Narrowband UVB Phototherapy

Psoralens+Ultravioletlight A (PUVA) Phototherapy

Request for [emailprotected]https://www.futuremarketinsights.com/askus/rep-gb-na-4297

By End User

Hospitals

Dermatology Clinics/Skin Care Centres

Wellness Centres

Home Care Settings

By Region

North America

Western Europe

Eastern Europe

View original post here:

Global North America and Europe Phototherapy Treatment Market is Poised to Register 6% Growth by the End of 2026 - 3rd Watch News

Background:Obesity and metabolic diseases including diabetes, hyperlipidemia, and hypertension are reportedly associated with an increased risk of psoriasis. However, few prospective studies have investigated the association of obesity and metabolic diseases with the risk of psoriasis.

Objective:To examine whether obesity or metabolic diseases increase the risk of psoriasis.

Methods:Participants were collected from 4 rounds (2001, 2005, 2009, and 2013) of the Taiwan National Health Interview Survey. Incident cases of psoriasis were identified from the National Health Insurance database. Participants were followed from the time of the National Health Interview Survey interview until December 31, 2017, or until a diagnosis of psoriasis was made or the participant died. The Cox regression model was used for the analyses.

Results:Of 60,136 participants, 406 developed psoriasis during 649,506 person-years of follow-up. Compared to participants with a BMI of 18.5-22.9, the adjusted hazard ratios (aHR) of psoriasis were 1.34 (95% CI 1.05-1.71) for a BMI of 25.0-29.9 and 2.70 (95% CI 1.95-3.72) for a BMI 30. Neither individual nor multiple metabolic diseases were associated with incident psoriasis. Participants with a BMI 30 were at significantly higher risk of both psoriasis without arthritis (aHR 2.60; 95% CI 1.85-3.67) and psoriatic arthritis (aHR 3.96; 95% CI 1.45-10.82).

Conclusion:Obesity, but not metabolic diseases, significantly increased the risk of psoriasis.

Keywords:Diabetes mellitus; Hyperlipidemia; Hypertension; Metabolic syndrome; Obesity; Psoriasis.

Excerpt from:

Obesity, but Not Metabolic Diseases, Is Associated With Risk of Psoriasis: A Population-Based Cohort Study in Taiwan - DocWire News

The exclusion of patients with worsening psoriasis from meta-analyses of trials that examine biologic therapies for type-plaque psoriasis reveal that serious adverse events (SAEs) are higher with biologic therapies than placebo, which suggest that findings from many meta-analyses do not reflect the real-world safety of biologic agents for psoriasis. This is according to a study research published in the British Journal of Dermatology.

In this study, researchers from France analyzed 51 randomized clinical trials in the Living Network Cochrane Review that compared a biologic therapy to placebo in patients with moderate to severe plaque psoriasis who required systemic treatment (N=24,820).

Trials included in this analysis included 1 anti-tumor necrosis factor (TNF) alpha arm, 1 anti-interleukin (IL)-17 arm, 1 anti-IL-23 arm, and 1 anti-IL-12/23 arm. The primary outcome of the analysis included the number of SAEs with biologic agents vs placebo after cases of psoriasis worsening were excluded. An additional secondary outcome included the number of adverse events (AEs) of special interest.

The mean age of the overall population was 45 years, and the mean baseline PASI score was 20.5. A higher percentage of patients included in all 51 trial were men compared with women (69% vs 31%, respectively). Approximately 25% (n=6287) of the population were randomly assigned to a placebo group.

In the analysis that included cases of psoriasis worsening, there was no statistically significant difference between biologic therapies and placebo in terms of the risk for occurrence SAEs (risk ratio [RR], 1.09; 95% CI, 0.88-1.36; P =.43). When the investigators excluded cases of psoriasis worsening, however, biologicl therapy was associated with a significantly higher risk for SAEs (RR, 1.30; 95% CI, 1.02-1.65; P =.03).

Separated by drug classes, the analysis revealed RRs of 1.68 (95% CI, 1.11-2.54; P =.01) for anti-TNF-alpha, 1.28 (95% CI, 0.88-1.85; P =.20) for anti-IL-17, 0.95 (95% CI 0.59-1.52; P =.83) for anti-IL-23, and 1.18 (95% CI 0.72-1.94; P =.51) for anti-IL-12/23. The small number of AEs of special interest in these analyses prevented the researchers from examining this outcome.

According to the investigators, the reporting of psoriasis worsening has changed over time, which made indirect comparisons not possible by network meta-analysis.

Based on these findings, the investigators added that the results for SAEs overall and SAEs excluding disease worsening should be presented in the results of RCTs and so in systematic reviews and meta-analyses.

Reference

Afach S, Chaimani A, Evrenoglou T, et al. Meta-analysis results do not reflect the real safety of biologics in psoriasis [published online May 23, 2020]. Br J Dermatol. doi: 10.1111/bjd.19244

Read this article:

More SAEs With Biologic Agents vs Placebo in Treatment of Psoriasis? - Dermatology Advisor

Psoriasis, superficial fungal infections, seborrheic dermatitis, actinic keratosis, and herpes simplex were the most common dermatologic diseases observed in patients with coronavirus disease 2019 (COVID-19) up to 3 years before their COVID-19 diagnosis, according to study research published in Dermatologic Therapy. Psoriasis was most common in the 3 months prior to a COVID-19 diagnosis in this study, which the researchers suggest could have been caused by the stress burden associated with the pandemic.

The retrospective study included 93 patients with COVID-19 (mean age, 55.2819.32 years) who had been admitted to a dermatology outpatient clinic in Turkey in the last 3 years before receiving a diagnosis of COVID-19. Patients were categorized as those who presented to the clinic in the last 3 months, 1 year, and 3 years prior to the COVID-19 diagnosis. A total of 6 patients from the overall cohort were in intensive care, whereas 4 became exitus.

Superficial fungal infections (25.8%), seborrheic dermatitis (11.8%), actinic keratosis (10.8%), psoriasis (6.5%), and eczema (6.5%) were the most common dermatologic conditions in the patients with COVID-19 who had dermatologic diseases 3 years prior to their infection. There were 52 patients with COVID-19 who visited a dermatology clinic for dermatologic diseases in the last year for superficial fungal infections (21.2%), seborrheic dermatitis (13.5%), actinic keratosis (11.5%), psoriasis (9.6%), herpes simplex (5.8%), and eczema (5.8%).

A total of 17 patients with COVID-19 (median age, 58 years) presented to a dermatology outpatient clinic for the last 3 months prior to their COVID-19 diagnosis. In these patients, the most common dermatologic diseases were superficial fungal infections (25%), psoriasis (20%), and viral skin diseases (15%).

Limitations of the study included the small sample size, retrospective design, and the inclusion of patients from a single center in Turkey.

Based on their findings, the researchers wrote that the potential similarity between cutaneous and mucosal immunity and immunosuppression suggests that patients with certain dermatologic diseases are particularly more vulnerable to the COVID-19.

Reference

Kutlu , Metin A. Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19? [published online May 5, 2020]. Dermatol Ther. doi: 10.1111/dth.13509

Read the original here:

Psoriasis, Fungal Infections, Are Common in Patients With COVID-19 - Dermatology Advisor

New Delhi, Jul 10 (PTI) India''s drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, officials told PTI on Friday.

Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon, for restricted emergency use for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.

"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medicine experts from AIIMS, among others, for treatment of cytokine release syndrome, an official told PTI.

"It is already an approved drug of Biocon for treating psoriasis for last many years," the official said.

Written informed consent of each patient is required before the use of this drug, he said. PTI PLB RAXRAX

Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: PTI

Read the rest here:

Psoriasis injection okayed for limited use to treat COVID patients: Drug controller - Outlook India

Psoriasis Treatment Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Psoriasis Treatment Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of This Report:

https://www.a2zmarketresearch.com/sample?reportId=273738

Top Key Players Profiled in This Report:

Novartis International AG, Johnson & Johnson, Pfizer Inc., Merck and Co. Inc., AbbVie and Amgen, Eli Lilly

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Psoriasis Treatment market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Psoriasis Treatment markets trajectory between forecast periods.

Get up to 20% Discount on this Premium[emailprotected]:

https://www.a2zmarketresearch.com/discount?reportId=273738

Reasons for buying this report:

Table of Contents:

Global Psoriasis Treatment Market Research Report

Chapter 1 Psoriasis Treatment Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Psoriasis Treatment Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=273738

See the rest here:

Massive Growth in Psoriasis Treatment Market Set to Witness Huge Growth by 2026 | Novartis International AG, Johnson & Johnson, Pfizer Inc., Merck...

What is psoriasis? Psoriasis is a skin condition where your body makes new skin cells quickly. In about 80 to 90% of people with psoriasis, these skin cells build up in thick, scaly patches called psoriasis plaques, according to the American Academy of Dermatology (AAD). The condition is not contagious.

More than 8 million people in the U.S. have psoriasis, and it usually starts in the teen years or early 20s, though it can strike at any age, reports the National Psoriasis Foundation (NPF). It can develop in people of any race, and is more common in people who have a family member with the condition.

Dr. Carolyn Jacob, medical director of Chicago Cosmetic Surgery and Dermatology and a member of the American Academy of Dermatology (AAD), was diagnosed with psoriasis 36 years ago. Its what got me into dermatology, she said.

Untreated, people with psoriasis can leave a trail of unsightly scales that make them want to stay home. Most people dont care for that, said Dr. Amy McMichael, chair of the dermatology department at Wake Forest Baptist Health in North Carolina and a member of the American Academy of Dermatology. Now we can get those patients to where they have a very manageable disease.

Most people with psoriasis develop itchy, scaly plaques that are usually white or silver. They often crop up on the knees, elbows, lower back or scalp. On the scalp, they can spread to psoriasis of the face.

Less-common types of psoriasis can cause tiny pink bumps, skin thats sore and red, pus-filled bumps on the hands and feet or other skin problems. You can have more than one type of psoriasis.

Its also possible to have psoriasis with arthritis, where the psoriasis affects the joints. According to the NPF, 30 percent of people with psoriasis will go on to develop psoriatic arthritis.

Trending stories,celebrity news and all the best of TODAY.

What causes psoriasis? The immune system plays a role. With psoriasis, the white blood cells, or T-cells, in the bodys immune system attack the skin cells. The body responds by making more skin cells, which build up on top of the skin.

Theres also a genetic factor behind who gets psoriasis. But some people get psoriasis even though they dont have the genes that increase their risk, according to the AAD. And its possible that some people who do have the genes that increase their risk never develop psoriasis. Researchers think exposure to a trigger might kickstart psoriasis in people who are more likely to develop it.

There are certain triggers that can cause psoriasis for the first time. These triggers can also cause psoriasis flare-ups.

Triggers linked with psoriasis, according to the AAD:

Not every trigger causes flare-ups in every person with psoriasis, so its important to watch your symptoms and try to determine what could be causing them.

Your dermatologist will look over your skin, nails and scalp to check for signs of psoriasis, and ask about your symptoms, joint problems, family history and possible triggers.

Examining a skin sample under a microscope can help confirm a psoriasis diagnosis.

Psoriasis is almost always a lifelong condition. We dont have a cure, but we have many medications now that can make you feel like you dont have psoriasis, Jacob said. The medications have advanced so far since when I was diagnosed they used to call it the heartbreak of psoriasis.'

McMichael recalls an 18-year-old patient with severe psoriasis the plaques covered her body and she needed a wheelchair to get around. She had been through all the medications we had. Now you never see a patient like that, she said. Today, if one medication doesnt work there are a lot more to try. That has made the lives of psoriasis patients so much easier, she said.

According to the NPF, psoriasis treatment options include:

While todays treatments are highly effective, its often necessary to use a combination of different treatments to achieve clear or nearly clear skin and sometimes it can take months, or even years, to find a treatment regimen that works well for you, according to the NPF. But reducing your psoriasis is an important goal. Not only will it make your skin feel better, itll help improve your overall health, including any depression that may be related to your psoriasis; it can also reduce your risk of other conditions, such as diabetes and cardiovascular disease.

People with psoriasis and their providers can use the NPFs treatment targets for guidance on how soon results can be expected when trying out medication options. The NPF says that after 3 months on a medication, psoriasis should only appear on 1% or less of your body surface area, though 75% improvement is also acceptable. But if you havent reached 1% or less psoriasis on your body after 6 months on the treatment regimen (and if you havent had an acceptable response after 3 months), the NPF recommends discussing other treatment options with your doctor.

Additionally, if youve achieved success with a treatment regimen, but it stops working well, talk to your doctor about finding another treatment solution for your psoriasis.

Its one of my favorite skin conditions to treat because there are so many options to make it better, Jacob said. The new biologics work so well we can get peoples skin clear so they feel like they dont have psoriasis I forget I have it now.

See more here:

Psoriasis: Treatments, medication, symptoms and more - TODAY - TODAY

Photo credit: Hearst Owned

From Oprah Magazine

Millions of Americans have psoriasis, which can cause patches of red or scaly skin to appear around the body. And because these flare-ups can occur anywhereincluding the hands, legs, face, and neck, all of which can be difficult to covershame and embarrassment have traditionally been part and parcel of having the disease. But that's starting to change, partly thanks to efforts by women like Angelique Miles and Joni Kazantzis, who use blogs and social media platforms to advocate for psoriasis patients and work to destigmatize the condition. We recently caught up with both of them to discover how they changed their way of thinking about psoriasis and kicked self-consciousness to the curb. Their words will resonate with anyone struggling with their confidence, regardless of the skin they're in.

As a 13-year-old with psoriasis on her scalp and forehead, Angelique Miles did everything she could to hide it. At the time, there were no available medications to treat the disease. I had bangs and I remember a girl said to me once, You know you can still see it, Miles recalls. It was traumatizing.

That was the early 80s, and there wasnt that much doctors could do. Miles dermatologist at the time basically told her to try a tar shampoo on her scalp, and that was it. It wasnt until her twenties that Miles discovered NYUs medical center, where they had a specific division for psoriasis. She started going twice a week for UVB treatment and, through an ongoing process with her doctorand through lots of trial and errorMiles was able to find the right medications and biologics to keep flare-ups to a minimum and better control her psoriasis.

Here's how the former music publishing executive turned fitness influencer and health advocate rediscovered her confidence.

A therapist once told me that my skin is the largest organ and I have to learn to accept and love it, says Angelique. Thats not to say I could still do without my psoriasis, but I now wear dresses in the summer or go to the beach. Other people can tell if youre confident, and giving off that vibe makes them not notice your skin as much. Its liberating.

Story continues

It seems like everybody knows someone with it and celebrities are talking about it more and more, she says, so theres more awareness these days.

Fitness has always been a big part of my life and being in good shape really contributes to my confidence, says Angelique. I used to start every day at the gym, but recently I bought a Peloton bike and I also do some virtual training sessions and online workouts.

One morning, when Joni was 15, she woke up covered in spots. I had no symptoms before that, but my grandmother lived with us and she had psoriasis, so she knew what it was right away, she recalls. I was so young and insecure at the time, so it was a struggle back then.

Joni has continually worked with her doctor to find a medication that keeps her psoriasis mostly in check; she now injects a biologic every few weeks. She still has to work on managing triggers like stress that can cause it to reappear. The one silver lining to it all: Joni believes that being forced to grow up with psoriasis has made her stronger and more able to deal with it as an adult. Heres her approach.

I make sure that whatever I wear feels good, nothing too tight or made with a synthetic material that irritates my skin, says Joni.

In the summer, I live in maxi dresses, says Joni. They keep me cool and give me the opportunity to be covered, but I can also lift the dress up to expose my legs if I want, since the sun helps my psoriasis.

I work in advertising and stand in front of people a lot to make presentations, says Joni. I make sure I have a loose cardigan or something that covers up my skin so that it doesnt take peoples attention away from what Im saying.

Even though I feel confident most of the time, there are still moments when I see someone looking at my skin or moving away from me and it takes me back to how I felt as a teenager, says Joni. In that moment, I tell myself that my psoriasis is a part of who I am. It has been around for all the major events in my life: graduating from college, getting married, and having my two daughters. Its part of what makes me, me.

You Might Also Like

Go here to read the rest:

My Psoriasis Doesnt Get in the Way of My Body Confidence - Yahoo Lifestyle

Global Psoriatic Arthritis Treatment Market: Overview

The demand within the global psoriatic arthritis treatment market has been rising on account of advancements in the field of healthcare and biosimilar analysis. The occurrence of psoriatic arthritis can place an extremely negative toll on the overall health of individuals. This is because psoriatic arthritis is more severe than any other form of arthritis. Under psoriatic arthritis, patients suffering from a skin condition called psoriases start to exhibit extreme symptoms of arthritis. This results in excessive pain, uneasiness, and discomfort for the sufferer, often necessitating emergency dosage of steroids. Hence, there is a dire need to ensure that psoriatic arthritis is controlled which in turn gives an impetus to the growth of the global market. The revenue scale of the global psoriatic arthritis treatment market shall improve alongside advancements in the field of geriatric care.

Get Sample Copy of the Report @https://www.tmrresearch.com/sample/sample?flag=B&rep_id=5495

There is no permanent treatment for psoriatic arthritis, and it can only be controlled with proper medication. The discomfort suffered by people affected with psoriatic arthritis is abysmal. Owing to the aforementioned factors, the global psoriatic arthritis treatment market is projected to attract the attention of the medical fraternity in the years to follow. The demand for psoriatic arthritis is projected to reach new heights in the years to follow.

The global psoriatic arthritis treatment market can be segmented on the basis of the following parameters: drug class, route of administration, and region. Based on drug class, the global psoriatic arthritis treatment market can be segmented into Disease-modifying Antirheumatic Drugs (DMARDs), Nonsteroidal Antiinflammatory Drugs (NSAIDs), and biologics. Based on route of administration, the global psoriatic arthritis treatment market can be segmented into orals, topical, and injectables.

Global Psoriatic Arthritis Treatment Market: Notable Developments

Several advancement in the competitive landscape have become a key characteristic of the global psoriatic arthritis treatment market in recent times.

Request TOC of the Report @https://www.tmrresearch.com/sample/sample?flag=T&rep_id=5495

Global Psoriatic Arthritis Treatment Market: Growth Driver

The occurrence of psoriatic arthritis is preceded by the severity of psoriasis in individuals. Hence, the field of dermatology needs to be work in conjunction with other medical departments in order to treat and control psoriatic arthritis. Hence, the global psoriatic arthritis treatment market shall expand alongside advancements in the field of dermatology. Furthermore, the availability of over-the-counter drugs for treatment of psoriatic arthritis propelled demand within the global market.

The joints suffer severe pain during psoriatic arthritis treatment, and the patients need to be quick recourse treatments. In a lot of cases, psoriatic arthritis poses a risk of permanent damage of joints. For this reason, the demand for psoriatic arthritis treatment has been rising at a stellar pace.

Global Psoriatic Arthritis Treatment Market: Regional Outlook

On the basis of geography, the global psoriatic arthritis treatment market can be segmented into North America, Europe, Asia Pacific, the Middle East and Africa, and Asia Pacific. The psoriatic arthritis treatment market in North America is expanding alongside advancements in the field of regional healthcare.

The global psoriatic arthritis treatment market can be segmented as:

Route of Administration

Read Comprehensive Overview of Report @https://www.tmrresearch.com/psoriatic-arthritis-treatment-market

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Link:

Psoriatic Arthritis Treatment Market Type, Share Size, Analysis Trends, Demand and Outlook 2028 - Cole of Duty

With psoriasis and obstructive sleep apnea (OSA) sharing various comorbidities and having a common pathogenesis of inflammatory and immune imbalance, many studies have examined the association between the two conditions. However, the results of these studies have differed. In order to evaluate the evidence on the bidirectional association of psoriasis and OSA, Ching-Chi Chi, MD, MMS, DPhil, Tzong-Yun Ger, MD, and Yun Fu, MD, conducted a systematic review and meta-analysis of case-control, cross-sectional, and cohort studies in the MEDLINE and Embase databases.

Exploring the Data

The researchers used the Newcastle-Ottawa Scale to evaluate the risk of bias of included studies and performed random-effects model meta-analysis to calculate pooled odds ratio (ORs) with 95% confidence intervals (CIs) for case-control and cross-sectional studies as well as pooled incidence rate ratio (IRR) with 95% CIs for cohort studies in association between psoriasis and OSA. Four case-control or cross-sectional studies and three cohort studies with a total of 5.8 million subjects were included.

Increased risk of OSA among patients with psoriasis was found in one cohort study, one cross-sectional study, and two case-control studies. Meta-analysis of the latter three showed a significant association of psoriasis with OSA among nearly 300,000 study subjects, with a pooled OR of 2.60, indicated that patients with psoriasis are 2.6-fold more likely to develop OSA when compared with patients without psoriasis, adds Dr. Ger (Figure 1). Although these three studies had considerable statistical heterogeneity, all had consistently positive results. In the cohort study, patients with mild psoriasis had a consistently increased risk of OSA (adjusted IRR, 1.36), as did those with severe psoriasis (adjusted IRR, 1.53) and psoriatic arthritis (adjusted IRR, 1.98).

Conversely, a consistent increase in psoriasis among patients with OSA was found across three cohort studies and one case-control study. A meta-analysis of the cohort studies showed a significant association of OSA with psoriasis (polled IRR, 2.52) across more than 5.5 million study subjects, with no statistical heterogeneity within the studies (Figure 2). After excluding one study with a high risk of bias in the representativeness of the exposed cohortall were nursesthe association of OSA with psoriasis remained positive (pooled IRR, 2.47). A significantly increased odds for psoriasis in relation to OSA was seen in the one case-control study (adjusted OR, 13.31).

Looking Ahead

Drs. Ger and Chi note the need for future research investigating the relationship between OSA and psoriasis in patients with varying races/ethnicities and from various regions, as well as the need for studies to confirm the mechanism(s) behind the relationship between the two conditions.

In the meantime, Dr. Ger suggests that all patients with psoriasis be made aware of their increased risk for OSA as a comorbidity that should not be overlooked. This patient population should be asked about sleep quality, and those with snoring at night, daytime sleepiness, and insomnia should be considered for polysomnography, consultation with a pulmonologists, or both. On the other hand, physicians should inquire about skin problems with their patients with OSA. Those suspected of having psoriasis should be referred to a dermatologist for further evaluation and treatment.

Bidirectional Association Between Psoriasis and Obstructive Sleep Apnea: A Systematic Review and Meta-Analysishttps://www.nature.com/articles/s41598-020-62834-x

See the article here:

The Bidirectional Association Between Psoriasis & OSA - Physician's Weekly

New data from a head-to-head study comparing risankizumab-rzaa to secukinumab in patients with moderate to severe plaque psoriasis were recently presented online at the American Academy of Dermatology virtual annual meeting.

In this 52-week, phase 3b, open-label, active-comparator study, patients were randomized to receive risankizumab 150mg subcutaneously (n=164) at baseline, week 4, then every 12 weeks thereafter, or secukinumab 300mg subcutaneously at baseline, weeks 1, 2, 3, and 4, then every 4 weeks thereafter. The co-primary end points were the proportion of patients with a 90% reduction in the Psoriasis Area and Severity Index score (PASI 90 response) at week 16 (noninferiority) and at week 52 (superiority) from baseline.

Results showed that the study met both primary end points of noninferiority and superiority. A greater proportion of patients treated with risankizumab achieved a PASI 90 response at week 16 (74% vs 66%) and at week 52 (87% vs 57%; P <.001) compared with secukinumab.

Risankizumab also met key secondary end points including a superior rate of complete skin clearance (PASI 100 response) at week 52 compared with secukinumab (66% vs 40%; P <.001). Moreover, 88% of patients treated with risankizumab achieved a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) at week 52 compared with 58% of patients treated with secukinumab (P <.001).

Risankizumab and secukinumab demonstrated comparable rates of adverse reactions. The most common were nasopharyngitis, upper respiratory tract infection, headache, arthralgia and diarrhea.

Risankizumab, an interleukin-23 antagonist, is marketed under the trade name Skyrizi and is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Secukinumab, an interleukin-17A antagonist, is marketed under the trade name Cosentyx and is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is also approved for the treatment of active psoriatic arthritis or ankylosing spondylitis in adults.

For more information visit abbvie.com.

See original here:

Superior Skin Clearance Observed With Risankizumab in Head-to-Head Psoriasis Study - Monthly Prescribing Reference